| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10911264 | Lung Cancer | 2012 | 6 Pages |
Abstract
Though we found that EGFR WT/KRAS mutant advanced NSCLC patients are associated with an increased resistance to treatment, specific mutant KRAS may account for differential sensitivity to an EGFR-TKI. KRAS codon 13 mutants are those who seem to experience the worse clinical outcome.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Giulio Metro, Rita Chiari, Simona Duranti, Annamaria Siggillino, Matthias J. Fischer, Diana Giannarelli, Vienna Ludovini, Chiara Bennati, Luca Marcomigni, Alice Baldi, Michele Giansanti, Vincenzo Minotti, Lucio Crinò,